The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

Similar changes in clinical signs, symptoms, pruritus, and quality of life were observed with lebrikizumab vs dupilumab among patients with atopic dermatitis. Lebrikizumab shows comparable efficacy to ...

Lebrikizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Rhinosinusitis. According to GlobalData, Phase III drugs for Rhinosinusitis have a 75% phase ...

Lebrikizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Nasal Polyps (Nasal Polyposis). According to GlobalData, Phase III drugs for Nasal Polyps (Nasal ...

Sustained improvement in pruritus and sleep measures were reported among patients with atopic dermatitis who received lebrikizumab treatment for 52 weeks, irrespective of the frequency at which ...

A team of scientists from the Cluster of Excellence "Balance of the Microverse" has discovered a previously unknown rejuvenation mechanism in unicellular organisms. They studied unicellular ...

University of Queensland researchers have discovered a mechanism in DNA that regulates how disease-causing mutations are inherited. The research paper has been published in Cell Metabolism.

RWKV is an RNN with transformer-level LLM performance. It can be directly trained like a GPT (parallelizable). So it's combining the best of RNN and transformer - great performance, fast inference, ...

McDonough, Peter Shin, Doh C. and Moisés, José Álvaro 1998. Democratization and Participation: Comparing Spain, Brazil, and Korea. The Journal of Politics, Vol. 60 ...

Problems at a contract manufacturing organisation have scuppered Eli Lilly’s hopes of a timely FDA approval for lebrikizumab, its IL-13 inhibitor for the treatment of atopic dermatitis or eczema.